to see the effect of Standard medical therapy along with rifaximin intervention vs. standard medical therapy alone on muscle wasting in patients with cirrhosis : A PILOT Randomized Controlled Trial
Phase 3
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2023/04/051474
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients with cirrhosis (Child A and B) and sarcopenia
Exclusion Criteria
1.Patients with history of overt hepatic encephalopathy (HE) or those who develop HE during treatment
2.Patients with sepsis, active GI bleed or acute kidney injury
3.Known cases of hepatocellular carcinoma
4.Any severe chronic illness including congestive heart failure, chronic kidney disease, neuromuscular disorders or HIV
5.History of any chronic drug intake such as corticosteroids
6.History of drugs postulated to increase muscle mass such as testosterone, growth hormone, anabolic steroids
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method